Go to main content
Back to Back to integrum.se
SV EN

Integrum Investor News

Martin bild intervju

Martin Hillsten on the directed share issue

Integrum’s CEO Martin Hillsten sees that increased financial stability will enable the company to more quickly seize the opportunities now opening up in both the US and Ukraine.

Published

R5__8884

Integrum has completed a directed share issuesion

The company will receive approximately SEK 22.9 million before deduction of transaction costs. Investors include Cicero Fonder, Nowo Fund Management, Curam Holding, Maria Anderkvist, Förvaltnings AB Grötlingboudd,...

Published

SRA copy

First U.S. patient implanted with e-OPRA in clinical study

A clinical study led by Shirley Ryan AbilityLab has reached its first milestone, with the first U.S. patient implanted with e-OPRA™ – a key step in the development of implantable intelligent bionics.

Published

Q1 2627

Integrum's Q1 report

Read Integrum’s interim report for the first quarter of the company’s financial year.

Published

Martin Hillsten Louise Wahlin

Watch Integrum's Q1 presentation

On Thursday September 3rd 2026, CEO Martin Hillsten and CFO Louise Wåhlin presented the company’s results for the first quarter of 2026/27. Watch the presentation here.

Published

Notice of Annual General Meeting

The shareholders of Integrum are hereby invited to the Annual General Meeting on 29 September 2026 at 16:00 at GoCo Health Innovation City.

Published

bcfe998a-f3c6-47fe-8667-c0dd77dc522a

CEO Martin Hillsten in Börsvärlden interview

In an interview with Börsvärlden, our CEO Martin Hillsten talks about the company's next phase. After a year marked by transformation, cost savings and a strengthened commercial organization, the company...

Published

Cookies

This website uses cookiesfor statistics and user experience.

This website uses cookies to improve your user experience, to provide a basis for improvement and further development of the website and to be able to direct more relevant offers to you.

Feel free to read our privacy policy. If you agree to our use, choose Allow all. If you want to change your choice afterwards, you will find that option at the bottom of the page.